iBio, Inc. (33)
Browse by Contract Category
Contracts
-
Underwriting Agreement, dated December 8, 2020, between iBio, Inc. and Cantor Fitzgerald & Co
(Filed With SEC on December 9, 2020)
-
Employment Agreement dated October 30, 2020 by and between iBio, Inc. and Randy J. Maddux, effective December 1, 2020
(Filed With SEC on November 3, 2020)
-
Description of Securities of iBio, Inc
(Filed With SEC on October 13, 2020)
-
Indemnification Agreement by and between iBio, Inc., John Delta and TechCXO, LLC dated July 13, 2020
(Filed With SEC on October 5, 2020)
-
Consulting Agreement by and between iBio, Inc. and TechCXO, LLC, dated July 8, 2020
(Filed With SEC on October 5, 2020)
-
Amendment No. 1 to Equity Distribution Agreement, dated July 29, 2020, by and between iBio, Inc. and UBS Securities LLC
(Filed With SEC on July 29, 2020)
-
Transition Agreement, dated June 12, 2020, between Robert Kay and iBio, Inc
(Filed With SEC on June 17, 2020)
-
Form of Stock Option Agreement
(Filed With SEC on June 17, 2020)
-
Equity Distribution Agreement, dated June 17 2020, by and between iBio, Inc. and UBS Securities, LLC
(Filed With SEC on June 17, 2020)
-
Purchase Agreement, dated as of May 13, 2020, between iBio, Inc. and Lincoln Park Capital Fund, LLC
(Filed With SEC on May 14, 2020)
-
Amended and Restated Executive Employment Agreement, dated as of April 21, 2020, between iBio, Inc. and Thomas F. Isett
(Filed With SEC on April 27, 2020)
-
Purchase Agreement, dated March 19, 2020, between the Company and Lincoln Park Capital Fund, LLC
(Filed With SEC on March 20, 2020)
-
Registration Rights Agreement, dated March 19, 2020, between the Company and Lincoln Park Capital Fund, LLC
(Filed With SEC on March 20, 2020)
-
Master Joint Development Agreement, dated as of August 8, 2018, between the Company and Beijing CC-Pharming Ltd
(Filed With SEC on March 19, 2020)
-
Employment Agreement, dated as of March 10, 2020, between iBio, Inc. and Thomas F. Isett
(Filed With SEC on March 13, 2020)
-
Statement of Work 2, dated February 6, 2020, between the Company and Beijing CC-Pharming Ltd
(Filed With SEC on March 13, 2020)
-
Master Joint Development Agreement, dated as of August 8, 2018, between the Company and Beijing CC-Pharming Ltd
(Filed With SEC on March 13, 2020)
-
Warrant Exchange and Amendment Agreement, between the Company and certain Holders, dated February 20, 2020
(Filed With SEC on February 21, 2020)
-
Form of Promissory Note
(Filed With SEC on February 21, 2020)
-
Form of Amended and Restated Series B Warrant to Purchase Common Stock
(Filed With SEC on February 21, 2020)
-
Form of Amended and Restated Series A Warrant to Purchase Common Stock
(Filed With SEC on February 21, 2020)
-
Underwriting Agreement, dated October 25, 2019, by and between iBio, Inc. and A.G.P./Alliance Global Partners
(Filed With SEC on October 29, 2019)
-
Form of Leak-Out Agreement
(Filed With SEC on October 28, 2019)
-
Form of Series B Warrant to Purchase Common Stock
(Filed With SEC on October 28, 2019)
-
Form of Series A Warrant to Purchase Common Stock
(Filed With SEC on October 28, 2019)
-
Underwriting Agreement, dated October 25, 2019, by and between iBio, Inc. and A.G.P./Alliance Global Partners
(Filed With SEC on October 28, 2019)
-
Form of Leak-Out Agreement
(Filed With SEC on October 24, 2019)
-
Form of Underwriting Agreement
(Filed With SEC on October 24, 2019)
-
Form of Series B Warrant to Purchase Common Stock
(Filed With SEC on October 15, 2019)
-
Form of Series A Warrant to Purchase Common Stock
(Filed With SEC on October 15, 2019)
-
Form of Underwriting Agreement
(Filed With SEC on October 15, 2019)
-
2018 Omnibus Equity Incentive Plan, effective December 18, 2018
(Filed With SEC on August 26, 2019)
-
Form of Indemnification Agreement
(Filed With SEC on April 1, 2019)
